<DOC>
	<DOC>NCT01052103</DOC>
	<brief_summary>The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.</brief_summary>
	<brief_title>A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Clinical diagnosis of schizophrenia Patients must have been receiving monotherapy treatment for at least 3 months prior to study entry with one of 4 atypical antipsychotic medications (aripiprazole, olanzapine, risperidone, quetiapine) Disease symptoms must meet a certain range as assessed by the clinician Patients must have evidence of prominent negative symptoms of schizophrenia (i.e. blunted affect, emotional withdrawal, or motor retardation) Patients must be considered reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and be willing to perform all study procedures Patients must be able to understand the nature of the study and have given their informed consent Patients who are actively suicidal Patients who are pregnant or nursing Patients who have had electroconvulsive therapy (ECT) within 3 months of screening or who will have ECT at any time during the study Patients with uncorrected narrowangle glaucoma, history of or current seizure disorder, uncontrolled diabetes, certain diseases of the liver, renal insufficiency, uncontrolled thyroid condition or other serious or unstable illnesses Patients with Parkinson's disease, psychosis related to dementia or related disorders Patients with known Human Immunodeficiency Virus positive (HIV+) status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>